NBIX logo

Neurocrine Biosciences (NBIX) Shareholders equity

annual shareholders equity:

$2.59B+$357.70M(+16.03%)
December 31, 2024

Summary

  • As of today (May 29, 2025), NBIX annual stockholders equity is $2.59 billion, with the most recent change of +$357.70 million (+16.03%) on December 31, 2024.
  • During the last 3 years, NBIX annual shareholders equity has risen by +$1.22 billion (+88.48%).
  • NBIX annual shareholders equity is now at all-time high.

Performance

NBIX Shareholders equity Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXbalance sheet metrics

quarterly shareholders equity:

$2.54B-$54.00M(-2.09%)
March 31, 2025

Summary

  • As of today (May 29, 2025), NBIX quarterly stockholders equity is $2.54 billion, with the most recent change of -$54.00 million (-2.09%) on March 31, 2025.
  • Over the past year, NBIX quarterly shareholders equity has increased by +$149.60 million (+6.27%).
  • NBIX quarterly shareholders equity is now -6.74% below its all-time high of $2.72 billion, reached on September 30, 2024.

Performance

NBIX quarterly shareholders equity Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXbalance sheet metrics

Shareholders equity Formula

Shareholders Equity = Total Assets − Total Liabilities

NBIX Shareholders equity Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+16.0%+6.3%
3 y3 years+88.5%+82.3%
5 y5 years+306.6%+262.1%

NBIX Shareholders equity Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+88.5%-6.7%+82.3%
5 y5-yearat high+306.6%-6.7%+262.1%
alltimeall timeat high>+9999.0%-6.7%>+9999.0%

NBIX Shareholders equity History

DateAnnualQuarterly
Mar 2025
-
$2.54B(-2.1%)
Dec 2024
$2.59B(+16.0%)
$2.59B(-4.8%)
Sep 2024
-
$2.72B(+8.4%)
Jun 2024
-
$2.51B(+5.2%)
Mar 2024
-
$2.39B(+6.9%)
Dec 2023
$2.23B(+30.7%)
$2.23B(+11.5%)
Sep 2023
-
$2.00B(+8.0%)
Jun 2023
-
$1.85B(+10.0%)
Mar 2023
-
$1.68B(-1.4%)
Dec 2022
$1.71B(+24.3%)
$1.71B(+10.6%)
Sep 2022
-
$1.54B(+8.5%)
Jun 2022
-
$1.42B(+2.3%)
Mar 2022
-
$1.39B(+1.2%)
Dec 2021
$1.37B(+22.0%)
$1.37B(+2.1%)
Sep 2021
-
$1.35B(+5.2%)
Jun 2021
-
$1.28B(+6.1%)
Mar 2021
-
$1.21B(+7.1%)
Dec 2020
$1.13B(+76.8%)
$1.13B(+40.0%)
Sep 2020
-
$804.30M(-3.2%)
Jun 2020
-
$831.20M(+18.7%)
Mar 2020
-
$700.30M(+10.0%)
Dec 2019
$636.90M(+32.5%)
$636.90M(+10.9%)
Sep 2019
-
$574.51M(+18.8%)
Jun 2019
-
$483.71M(+18.2%)
Mar 2019
-
$409.27M(-14.9%)
Dec 2018
$480.76M(+29.2%)
$480.76M(+7.4%)
Sep 2018
-
$447.51M(+18.6%)
Jun 2018
-
$377.44M(+3.6%)
Mar 2018
-
$364.49M(-2.1%)
Dec 2017
$372.14M(+18.2%)
$372.14M(+7.1%)
Sep 2017
-
$347.51M(+0.7%)
Jun 2017
-
$345.24M(+39.7%)
Mar 2017
-
$247.14M(-21.5%)
Dec 2016
$314.88M(-25.8%)
$314.88M(-10.5%)
Sep 2016
-
$351.65M(-7.7%)
Jun 2016
-
$381.04M(-7.7%)
Mar 2016
-
$412.96M(-2.7%)
Dec 2015
$424.45M(+103.4%)
$424.45M(-5.0%)
Sep 2015
-
$446.94M(-4.3%)
Jun 2015
-
$466.94M(-3.7%)
Mar 2015
-
$484.73M(+132.3%)
Dec 2014
$208.70M(+73.3%)
$208.70M(-6.8%)
Sep 2014
-
$224.04M(-5.4%)
Jun 2014
-
$236.84M(-4.1%)
Mar 2014
-
$247.06M(+105.2%)
Dec 2013
$120.41M(-22.0%)
$120.41M(-6.9%)
Sep 2013
-
$129.29M(-4.9%)
Jun 2013
-
$136.02M(-6.2%)
Mar 2013
-
$144.95M(-6.1%)
Dec 2012
$154.37M(+156.9%)
$154.37M(+7.7%)
Sep 2012
-
$143.31M(-1.0%)
Jun 2012
-
$144.73M(+0.6%)
Mar 2012
-
$143.83M(+139.4%)
Dec 2011
$60.08M(+210.6%)
$60.08M(+4.0%)
Sep 2011
-
$57.75M(+126.0%)
Jun 2011
-
$25.56M(+11.2%)
Mar 2011
-
$22.99M(+18.9%)
Dec 2010
$19.34M
$19.34M(+16.2%)
DateAnnualQuarterly
Sep 2010
-
$16.65M(+34.1%)
Jun 2010
-
$12.41M(-25.8%)
Mar 2010
-
$16.72M(+322.9%)
Dec 2009
$3.95M(-89.2%)
$3.95M(+267.8%)
Sep 2009
-
$1.07M(-85.4%)
Jun 2009
-
$7.35M(-61.6%)
Mar 2009
-
$19.11M(-48.0%)
Dec 2008
$36.77M(-69.0%)
$36.77M(-42.2%)
Sep 2008
-
$63.65M(-20.3%)
Jun 2008
-
$79.84M(-19.1%)
Mar 2008
-
$98.67M(-16.9%)
Dec 2007
$118.70M(-62.3%)
$118.70M(-51.5%)
Sep 2007
-
$244.95M(-9.0%)
Jun 2007
-
$269.05M(-7.8%)
Mar 2007
-
$291.70M(-7.3%)
Dec 2006
$314.72M(-19.3%)
$314.72M(-3.6%)
Sep 2006
-
$326.48M(-9.8%)
Jun 2006
-
$361.77M(-5.7%)
Mar 2006
-
$383.83M(-1.6%)
Dec 2005
$390.10M(-0.9%)
$390.10M(-3.4%)
Sep 2005
-
$403.74M(+8.5%)
Jun 2005
-
$372.02M(-0.7%)
Mar 2005
-
$374.72M(-4.9%)
Dec 2004
$393.83M(+0.7%)
$393.83M(-4.5%)
Sep 2004
-
$412.56M(+0.2%)
Jun 2004
-
$411.54M(-3.3%)
Mar 2004
-
$425.40M(+8.8%)
Dec 2003
$391.12M(+74.4%)
$391.12M(+1.1%)
Sep 2003
-
$386.83M(+84.2%)
Jun 2003
-
$209.97M(-2.4%)
Mar 2003
-
$215.21M(-4.0%)
Dec 2002
$224.25M(-27.8%)
$224.25M(-13.7%)
Sep 2002
-
$259.83M(-6.3%)
Jun 2002
-
$277.23M(-5.7%)
Mar 2002
-
$293.93M(-5.3%)
Dec 2001
$310.39M(+90.2%)
$310.39M(+113.3%)
Sep 2001
-
$145.53M(+1.9%)
Jun 2001
-
$142.87M(-6.8%)
Mar 2001
-
$153.29M(-6.1%)
Dec 2000
$163.21M(+69.3%)
$163.21M(+100.4%)
Sep 2000
-
$81.44M(-6.2%)
Jun 2000
-
$86.85M(-5.6%)
Mar 2000
-
$92.04M(-4.5%)
Dec 1999
$96.40M(+33.9%)
$96.40M(+62.6%)
Sep 1999
-
$59.30M(-6.3%)
Jun 1999
-
$63.30M(-6.9%)
Mar 1999
-
$68.00M(-5.6%)
Dec 1998
$72.00M(-13.5%)
$72.00M(-8.5%)
Sep 1998
-
$78.70M(+0.4%)
Jun 1998
-
$78.40M(-4.6%)
Mar 1998
-
$82.20M(-1.2%)
Dec 1997
$83.20M(+14.3%)
$83.20M(+6.0%)
Sep 1997
-
$78.50M(+1.4%)
Jun 1997
-
$77.40M(+0.3%)
Mar 1997
-
$77.20M(+6.0%)
Dec 1996
$72.80M
$72.80M(+6.7%)
Sep 1996
-
$68.20M(-0.4%)
Jun 1996
-
$68.50M(+183.1%)
Mar 1996
-
$24.20M

FAQ

  • What is Neurocrine Biosciences annual stockholders equity?
  • What is the all time high annual shareholders equity for Neurocrine Biosciences?
  • What is Neurocrine Biosciences annual shareholders equity year-on-year change?
  • What is Neurocrine Biosciences quarterly stockholders equity?
  • What is the all time high quarterly shareholders equity for Neurocrine Biosciences?
  • What is Neurocrine Biosciences quarterly shareholders equity year-on-year change?

What is Neurocrine Biosciences annual stockholders equity?

The current annual shareholders equity of NBIX is $2.59B

What is the all time high annual shareholders equity for Neurocrine Biosciences?

Neurocrine Biosciences all-time high annual stockholders equity is $2.59B

What is Neurocrine Biosciences annual shareholders equity year-on-year change?

Over the past year, NBIX annual stockholders equity has changed by +$357.70M (+16.03%)

What is Neurocrine Biosciences quarterly stockholders equity?

The current quarterly shareholders equity of NBIX is $2.54B

What is the all time high quarterly shareholders equity for Neurocrine Biosciences?

Neurocrine Biosciences all-time high quarterly stockholders equity is $2.72B

What is Neurocrine Biosciences quarterly shareholders equity year-on-year change?

Over the past year, NBIX quarterly stockholders equity has changed by +$149.60M (+6.27%)
On this page